Pertussis (Whooping Cough) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pertussis (Whooping Cough) – Drugs In Development, 2024 report and make more profitable business decisions.
Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red watery eyes, and dry cough. Treatment includes antibiotics.
The Pertussis (Whooping Cough) drugs in development market research report provide comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pertussis (Whooping Cough) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 45 molecules, with 40 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pertussis (Whooping Cough) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pertussis (Whooping Cough) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pertussis (Whooping Cough) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AIM Vaccine Co LtdBeijing Minhai Biotechnology Co Ltd
Beijing Tiantan Biological Products Co Ltd
Bharat Biotech Ltd
Biological E Ltd
BioNet-Asia Co Ltd
Boryung Pharmaceutical Co Ltd
Butantan Institute
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
Chengdu Olymvax Biopharmaceuticals Inc
Chongqing Zhifei Biological Products Co Ltd
GC Biopharma Corp
GSK plc
ILiAD Biotechnologies LLC
Indian Immunologicals Ltd
Intravacc BV
KM Biologics Co Ltd
LG Chem Ltd
Novo Medi Sciences Pvt Ltd
Panacea Biotec Ltd
Port Polish Center for Technology Development
Sanofi
Serum Institute of India Pvt Ltd
Suzhou Weichao Biotechnology Co Ltd
Theriva Biologics Inc
University of Oulu
VaxForm LLC
Walvax Biotechnology Co Ltd
Wuhan Institute of Biological Products Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pertussis (Whooping Cough) reports